Journal ArticleDOI
Cancer immunotherapy – revisited
TLDR
The recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.Abstract:
Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.read more
Citations
More filters
Journal ArticleDOI
The secret ally: immunostimulation by anticancer drugs
TL;DR: The molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications, are discussed.
Journal ArticleDOI
Turning the corner on therapeutic cancer vaccines
TL;DR: Key steps are highlighted that are bringing the promise of therapeutic cancer vaccines within reach, including learning which vaccine approaches elicit the potent, balanced, and durable CD4 plus CD8 T cell expansion necessary for clinical efficacy.
Journal ArticleDOI
Classification of current anticancer immunotherapies
Lorenzo Galluzzi,Erika Vacchelli,José Manuel Bravo-San Pedro,Aitziber Buqué,Laura Senovilla,Elisa E. Baracco,Norma Bloy,Francesca Castoldi,Jean Pierre Abastado,Patrizia Agostinis,Ron N. Apte,Fernando Aranda,Maha Ayyoub,Philipp Beckhove,Jean-Yves Blay,Laura Bracci,Anne Caignard,Chiara Castelli,Federica Cavallo,Estaban Celis,Vincenzo Cerundolo,Aled Clayton,Mario P. Colombo,Lisa M. Coussens,Madhav V. Dhodapkar,Alexander M.M. Eggermont,Douglas T. Fearon,Wolf H. Fridman,Jitka Fucikova,Dmitry I. Gabrilovich,Jérôme Galon,Abhishek D. Garg,François Ghiringhelli,François Ghiringhelli,Giuseppe Giaccone,Giuseppe Giaccone,Eli Gilboa,Sacha Gnjatic,Axel Hoos,Anne Hosmalin,Anne Hosmalin,Anne Hosmalin,Dirk Jäger,Pawel Kalinski,Klas Kärre,Oliver Kepp,Rolf Kiessling,John M. Kirkwood,Eva Klein,Alexander Knuth,Claire E. Lewis,Roland S. Liblau,Roland S. Liblau,Roland S. Liblau,Michael T. Lotze,Enrico Lugli,Jean-Pierre Mach,Fabrizio Mattei,Domenico Mavilio,Ignacio Melero,Cornelis J. M. Melief,E. A. Mittendorf,Lorenzo Moretta,Adekunke Odunsi,Hideho Okada,Anna Karolina Palucka,Marcus E. Peter,Kenneth J. Pienta,Angel Porgador,George C. Prendergast,George C. Prendergast,Gabriel A. Rabinovich,Nicholas P. Restifo,Naiyer A. Rizvi,Catherine Sautès-Fridman,Hans Schreiber,Barbara Seliger,Hiroshi Shiku,Bruno Silva-Santos,Mark J. Smyth,Mark J. Smyth,Daniel E. Speiser,Daniel E. Speiser,Radek Spisek,Pramod K. Srivastava,James E. Talmadge,Eric Tartour,Sjoerd H. van der Burg,Benoît Van den Eynde,Benoît Van den Eynde,Richard G. Vile,Hermann Wagner,Jeffrey S. Weber,Theresa L. Whiteside,Jedd D. Wolchok,Jedd D. Wolchok,Laurence Zitvogel,Weiping Zou,Guido Kroemer +98 more
TL;DR: A critical, integrated classification of anticancer immunotherapies is proposed and the clinical relevance of these approaches is discussed.
Journal ArticleDOI
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Laurie Menger,Erika Vacchelli,Erika Vacchelli,Erika Vacchelli,Sandy Adjemian,Sandy Adjemian,Sandy Adjemian,Isabelle Martins,Isabelle Martins,Isabelle Martins,Yuting Ma,Yuting Ma,Yuting Ma,Shensi Shen,Shensi Shen,Shensi Shen,Takahiro Yamazaki,Takahiro Yamazaki,Takahiro Yamazaki,Abdul Qader Sukkurwala,Abdul Qader Sukkurwala,Abdul Qader Sukkurwala,Mickaël Michaud,Mickaël Michaud,Mickaël Michaud,Grégoire Mignot,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Eric Sulpice,Clara Locher,Clara Locher,Clara Locher,Xavier Gidrol,François Ghiringhelli,Nazanine Modjtahedi,Nazanine Modjtahedi,Nazanine Modjtahedi,Lorenzo Galluzzi,Lorenzo Galluzzi,Fabrice Andre,Fabrice Andre,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Oliver Kepp,Oliver Kepp,Oliver Kepp,Guido Kroemer +48 more
TL;DR: Rec retrospective clinical analyses revealed that the administration of the CG digoxin during chemotherapy had a positive impact on overall survival in cohorts of breast, colorectal, head and neck, and hepatocellular carcinoma patients, especially when they were treated with agents other than anthracyclines and oxaliplatin.
Journal ArticleDOI
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
TL;DR: The literature on the immunogenic effects of platinum is reviewed, the clinical advances using platinum as a cytotoxic compound with immune adjuvant properties are summarized, the limitations to these studies are discussed, and the gaps in the understanding of the immunologic effects of these drugs are discussed.
References
More filters
Journal ArticleDOI
Toll-dependent selection of microbial antigens for presentation by dendritic cells
TL;DR: It is shown that the efficiency of presenting antigens from phagocytosed cargo is dependent on the presence of TLR ligands within the cargo and the generation of peptide–MHC class II complexes is controlled by TLRs in a strictly phagosome-autonomous manner.
Journal ArticleDOI
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Douglas J. Schwartzentruber,David H. Lawson,Jon M. Richards,Robert M. Conry,Donald M. Miller,Jonathan S. Treisman,Fawaz Gailani,Lee B. Riley,Kevin C. Conlon,Barbara A. Pockaj,Kari Kendra,Richard L. White,Rene Gonzalez,Timothy M. Kuzel,Brendan D. Curti,Phillip D. Leming,Eric D. Whitman,Jai Balkissoon,Douglas S. Reintgen,Howard L. Kaufman,Francesco M. Marincola,Maria J. Merino,Steven A. Rosenberg,Peter L. Choyke,Don Vena,Patrick Hwu +25 more
TL;DR: In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine andInterleukin-2 than with interleuk in-2 alone.
Journal ArticleDOI
Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis.
TL;DR: The cytotoxic activity of immune thymus-derived lymphocytes (T cells) for 51Cr-labeled fibroblasts or macrophages infected with lymphocytic choriomeningitis (LCM) virus is restricted by the H-2 gene complex as mentioned in this paper.
Journal ArticleDOI
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
I. Jolanda M. de Vries,W. Joost Lesterhuis,Jelle O. Barentsz,Pauline Verdijk,J. Han van Krieken,Otto C. Boerman,Wim J.G. Oyen,Johannes J. Bonenkamp,Jan B.M. Boezeman,Gosse J. Adema,Jeff W.M. Bulte,Tom W. J. Scheenen,Cornelis J. A. Punt,Arend Heerschap,Carl G. Figdor +14 more
TL;DR: In vivo magnetic resonance tracking of magnetically labeled cells is feasible in humans for detecting very low numbers of dendritic cells in conjunction with detailed anatomical information and appears clinically safe and well suited to monitor cellular therapy in humans.
Journal ArticleDOI
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop,Karen S. Slobod,Martin Pule,Gregory A. Hale,Alexandra Rousseau,Colton Smith,Catherine M. Bollard,Hao Liu,Meng-Fen Wu,Richard Rochester,Persis Amrolia,Julia L. Hurwitz,Malcolm K. Brenner,Cliona M. Rooney +13 more
TL;DR: T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)-stimulated immunity has the potential to fill an important niche in targeted therapy for EBV-related cancers and the manufacturing methodology is robust and can be transferred readily from one institution to another without loss of reproducibility.
Related Papers (5)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more